GlassScriptPhysician profile
Benjamin T Esparaz
NPI 1275502940
$9,805.30
in general payments reported to CMS, 2019-2025
57 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,964 · 2020: $1,296 · 2021: $1,634 · 2022: $3,057 · 2023: $1,500 · 2024: $247 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.63 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $919.23 | 2019-2024 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $732.64 | 2019-2024 | |
| Genzyme Corporation | $727.50 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $570.37 | 2019-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $549.03 | 2019-2024 | Imfinzi, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $530.30 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $452.82 | 2019-2024 | |
| Astellas Pharma US INC | $411.16 | 2019-2025 | Xtandi, Padcev, Vyloy |
| Genentech USA, INC. | $363.02 | 2019-2023 | Rozlytrek, Tecentriq, Alecensa |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Eisai INC. | $342.71 | 2019-2023 | |
| Seagen INC. | $338.37 | 2019-2023 | Tukysa, Padcev |
| Alexion Pharmaceuticals, INC. | $301.85 | 2019-2022 | |
| Amgen INC. | $293.09 | 2019-2023 | Nplate, Vectibix |
| Lilly USA, LLC | $243.54 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Esparaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.